By integrating these assays (SAA, NfL and TDP-43 assessment) with conventional diagnostic tests, we can hopefully move closer to developing precise biological fingerprints of ALS to overcome the current limitations of clinically driven diagnosis [50]. With continuous refinement, these innovative tools promise to increase diagnostic accuracy, patient stratification, and efficacy in clinical trials, ultimately improving outcomes for ALS patients. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.